The role of myostatin and bone morphogenetic proteins in muscular disorders

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Skeletal muscle is the largest organ in the human body, and plays an important role in body movement and metabolism. Skeletal muscle mass is lost in genetic disorders such as muscular dystrophy, muscle wasting and ageing. Chemicals and proteins that restore muscle mass and function are potential drugs that can improve human health and could be used in the clinic. Myostatin is a muscle-specific member of the transforming growth factor (TGF)-β superfamily that plays an essential role in the negative regulation of muscle growth. Inhibition of myostatin activity is a promising therapeutic method for restoring muscle mass and strength. Potential inhibitors of myostatin include follistatin domain-containing proteins, myostatin propeptide, myostatin antibodies and chemical compounds. These inhibitors could be beneficial for the development of clinical drugs for the treatment of muscular disorders. Bone morphogenetic protein (BMP) plays a significant role in the development of neuromuscular architecture and its proper functions. Modulation of BMP activity could be beneficial for muscle function in muscular disorders. This review will describe the current progress in therapy for muscular disorders, emphasising the importance of myostatin as a drug target.

Original languageEnglish
Pages (from-to)147-154
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume6
Issue number2
DOIs
Publication statusPublished - 01-02-2006

Fingerprint

Myostatin
Bone Morphogenetic Proteins
Muscle
Muscles
Skeletal Muscle
Pharmaceutical Preparations
Follistatin
Inborn Genetic Diseases
Muscle Proteins
Muscular Dystrophies
Muscle Strength
Transforming Growth Factors
Human Body
Chemical compounds
Metabolism
Proteins
Antibodies
Aging of materials
Health
Modulation

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology
  • Pharmacology

Cite this

@article{e0842f3a02b7444c9e36678d94a756fe,
title = "The role of myostatin and bone morphogenetic proteins in muscular disorders",
abstract = "Skeletal muscle is the largest organ in the human body, and plays an important role in body movement and metabolism. Skeletal muscle mass is lost in genetic disorders such as muscular dystrophy, muscle wasting and ageing. Chemicals and proteins that restore muscle mass and function are potential drugs that can improve human health and could be used in the clinic. Myostatin is a muscle-specific member of the transforming growth factor (TGF)-β superfamily that plays an essential role in the negative regulation of muscle growth. Inhibition of myostatin activity is a promising therapeutic method for restoring muscle mass and strength. Potential inhibitors of myostatin include follistatin domain-containing proteins, myostatin propeptide, myostatin antibodies and chemical compounds. These inhibitors could be beneficial for the development of clinical drugs for the treatment of muscular disorders. Bone morphogenetic protein (BMP) plays a significant role in the development of neuromuscular architecture and its proper functions. Modulation of BMP activity could be beneficial for muscle function in muscular disorders. This review will describe the current progress in therapy for muscular disorders, emphasising the importance of myostatin as a drug target.",
author = "Kunihiro Tsuchida",
year = "2006",
month = "2",
day = "1",
doi = "10.1517/14712598.6.2.147",
language = "English",
volume = "6",
pages = "147--154",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "2",

}

The role of myostatin and bone morphogenetic proteins in muscular disorders. / Tsuchida, Kunihiro.

In: Expert Opinion on Biological Therapy, Vol. 6, No. 2, 01.02.2006, p. 147-154.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The role of myostatin and bone morphogenetic proteins in muscular disorders

AU - Tsuchida, Kunihiro

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Skeletal muscle is the largest organ in the human body, and plays an important role in body movement and metabolism. Skeletal muscle mass is lost in genetic disorders such as muscular dystrophy, muscle wasting and ageing. Chemicals and proteins that restore muscle mass and function are potential drugs that can improve human health and could be used in the clinic. Myostatin is a muscle-specific member of the transforming growth factor (TGF)-β superfamily that plays an essential role in the negative regulation of muscle growth. Inhibition of myostatin activity is a promising therapeutic method for restoring muscle mass and strength. Potential inhibitors of myostatin include follistatin domain-containing proteins, myostatin propeptide, myostatin antibodies and chemical compounds. These inhibitors could be beneficial for the development of clinical drugs for the treatment of muscular disorders. Bone morphogenetic protein (BMP) plays a significant role in the development of neuromuscular architecture and its proper functions. Modulation of BMP activity could be beneficial for muscle function in muscular disorders. This review will describe the current progress in therapy for muscular disorders, emphasising the importance of myostatin as a drug target.

AB - Skeletal muscle is the largest organ in the human body, and plays an important role in body movement and metabolism. Skeletal muscle mass is lost in genetic disorders such as muscular dystrophy, muscle wasting and ageing. Chemicals and proteins that restore muscle mass and function are potential drugs that can improve human health and could be used in the clinic. Myostatin is a muscle-specific member of the transforming growth factor (TGF)-β superfamily that plays an essential role in the negative regulation of muscle growth. Inhibition of myostatin activity is a promising therapeutic method for restoring muscle mass and strength. Potential inhibitors of myostatin include follistatin domain-containing proteins, myostatin propeptide, myostatin antibodies and chemical compounds. These inhibitors could be beneficial for the development of clinical drugs for the treatment of muscular disorders. Bone morphogenetic protein (BMP) plays a significant role in the development of neuromuscular architecture and its proper functions. Modulation of BMP activity could be beneficial for muscle function in muscular disorders. This review will describe the current progress in therapy for muscular disorders, emphasising the importance of myostatin as a drug target.

UR - http://www.scopus.com/inward/record.url?scp=32944469015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944469015&partnerID=8YFLogxK

U2 - 10.1517/14712598.6.2.147

DO - 10.1517/14712598.6.2.147

M3 - Review article

C2 - 16436040

AN - SCOPUS:32944469015

VL - 6

SP - 147

EP - 154

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 2

ER -